… Neurological diseases such as amyotrophic lateral sclerosis (… of new drugs and/or drug
screening for ALS treatment and … a potential therapeutic target in amyotrophic lateral sclerosis. …

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by progressive
loss of upper and lower motor neurons. Despite significant scientific efforts in the last …

… A limitation in moving such treatments from bench to bedside is a lack of pharmacodynamic
… in gauging biochemical responses to potential treatments. Treating c9ALS patient cells or a …

… its safety and efficacy and its use as a complementary therapy along with other approved
drugs. … Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded …

… This opposes the high attrition of drugs during bench-to-bedside translation … drug development.
These findings emphasize a careful application of these model systems for ALS therapy …

… 12 weeks of study drug treatment. One participant was … No serious AEs attributed to study
drug and no AEs of special … is rapidly advancing from the bench to the bedside in PD where a …

… of findings from bench to bedside of potentially effective … a mouse model of amyotrophic
lateral sclerosis. The efficacy of … effects for the treatment of amyotrophic lateral sclerosis. …

… the small study sample and the low treatment doses received by patients. Another silencing
… RNAi therapy from the bench to the bedside is the lack of an in vivo biomarker of therapeutic …

… drug from the bench to bedside is very expensive, laborious and slow process. The cost of
development and validation of potential therapeutic … with consecutive drug therapies until the …